MRSA genetic test boosts Cepheid

03/4/2008 | NYTimes.com · Sun (Baltimore), The

As infections caused by methicillin-resistant Staphylococcus aureus are gaining attention for causing more than 19,000 deaths per year in the U.S., Biotech firm Cepheid has found success with the rapid adoption of its genetic test designed to help hospitals quickly detect MRSA. "We're in the right place at the right time with the right technology," the company's chief medical officer said.

View Full Article in:

NYTimes.com · Sun (Baltimore), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI